Lacosamide is indicated for the treatment of partial-onset seizures in patients 1 month of age and older, as well as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

Insight:

Dosing: Initial dosage for monotherapy for the treatment of partial-onset seizures is 100 mg twice daily. Initial dosage for adjunctive therapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures is 50 mg twice daily.
Dosage forms: 50 mg, 100 mg, 150 mg, 200 mg tablets; 200 mg/20 mL single-dose vial for intravenous use; 10 mg/mL oral solution.
Adverse events (AEs): Most common AEs in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.
Mechanism of action: Inhibition of neuronal firing.
Manufacturer: ucbCARES

Sources:

vimpat-prescribing-information.pdf
Vimpat6002PPS0.JPG (531×567) (windows.net)